Owens & Minor, Rotech cancel merger

RICHMOND, Va. – Owens & Minor and Rotech Healthcare have mutually agreed to terminate their previously announced acquisition.  

Under the terms of the merger agreement, Owens & Minor has paid $80 million to Rotech Healthcare.  

“For many months, our teammates, along with the Rotech team, have worked tirelessly in cooperation with the Federal Trade Commission to close this transaction, and while we believe there would have been ample benefits to patients, payers and providers by adding Rotech to our Patient Direct business, the path to obtain regulatory clearance for this merger proved unviable in terms of time, expense and opportunity,” said Edward A. Pesicka, president & CEO, Owens & Minor. 

Owens & Minor in July 2024 announced that had entered into a definitive agreement to buy Rotech for $1.36 billion in cash. In April 2025, the company upsized a private offering from $600 million to $1 billion aggregate principal amount of senior secured notes to finance the acquisition, which it will redeem. 

Owens & Minor says it will continue to focus its efforts on growing its Patient Direct business, which includes Apria Healthcare and Byram Healthcare. Earlier this year, the company doubled down on the business when it announced plans to sell its Products and Healthcare Services business.  

“We are confident in our strategy,” Pesicka said. “The home-based care market is a dynamic, growing market and we are extremely well positioned to help those with chronic conditions get the care and service they need and deserve. Also, we continue to work with a number of interested parties around the potential sale of our Products and Healthcare Services business, and, in the meantime, we will continue to actively work to strengthen that business and tap into its significant upside.” 

Rotech has been said to be exploring a possible sale since mid-2023.  

• Related: Owens & Minor talks product play, synergy drivers  
• Related: Sleep, diabetes ‘lead the way’ at Owens & Minor